Opinion|Videos|November 26, 2024
Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02
This episode discusses the desired outcomes from the HERTHENA-Lung02 trial that would justify using HER3-DXd before platinum and pemetrexed chemotherapy while also exploring the potential benefits of amivantamab, including its PFS advantage and the observed trend toward improved OS in this treatment setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What outcomes do you need to see in HERTHENA-Lung02 to use it before platinum plus pemetrexed chemotherapy?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5